Innovative Approaches to Saving Patients Money on Prescription Drug Costs

Similar documents
Prescription Medicines: Costs in Context

July 13, Dear Secretary Price:

New Member Reference Guide Your guide to getting the most from your Part D coverage.

Transitioning to Express Scripts

Using Your Prescription. Drug Program. Answers to important questions about retail pharmacy and mail order purchasing

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS

RISING COSTS FOR PATENTED DRUGS DRIVE GROWTH OF PHARMACEUTICAL SPENDING IN THE U.S.

A Benefits Partner You Can Be Confident In

Commercial Pricing and Contracting 101

Statement. For. United States Senate Committee on Finance. June 8, :45 a.m.

TAKE A CLOSER LOOK at Biosimilars

.COM. Pharmaceutical Brand Management Achieving Managed Care Pull-Through Performance

Eaton Corporation Prescription Drug Benefit Managed by Express Scripts Frequently Asked Questions

FREQUENTLY ASKED QUESTIONS

An Economic Analysis of Generic Drug Usage in the U.S.

Policy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)

Understanding Biosimilars and Projecting the Cost Savings to Employers Update

Medical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs

SPECIALTY DRUGS AND SPIRALING COSTS

Pharmacy Benefit Drug Trends and Pipeline. Casey Robinson, PharmD, MBA, Cigna Pharmacy Management

OREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE. OPERATING PROCEDURES Updated: March 2018

The Future of Generic Pharmaceuticals

COMMUNITY OUTREACH STRATEGIES

Who is Best at Negotiating Pharmaceutical Rebates?

VALUE-BASED HEALTHCARE A MANUFACTURER S PERSPECTIVE PETER JUHN, MD, MPH VICE PRESIDENT AND GLOBAL HEAD, VALUE-BASED PARTNERSHIPS

CASE STUDY: USING MARKET FORCE TEMPLATE TO UNDERSTAND PHARMA RETAIL MARKETS IN FRANCE

Transparency Debate in PBM Industry Consumer Driven Healthcare Summit Sept , 2006 in Washington, DC. Marina Tackitt PBMI

White paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act

Hatch-Waxman: Driving Access, Savings & Innovation

Health Plan Optimization. Leveraging data to improve performance across the enterprise

REPORT 2 OF THE COUNCIL ON MEDICAL SERVICE (I-15) Pharmaceutical Costs (Resolution 207-I-14 and Resolution 228-I-14) (Reference Committee J)

How Plans and Providers Can Leverage Their HIPAA Investment for Productively and Profitability

Pharmamarketing - strategic challenges

Drafting Pharmacy Benefit Manager Contracts: Controlling Costs, Avoiding Hidden Fees

2009 National Pharmacy Study SM

NEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY

2016 OptumRx Trend Insights

Drugs, Dollars and Dynamics: The Ups and Downs of Generic Pharmaceutical Pricing. Presented by: Pharmacy Healthcare Solutions, Inc.

Are Your Workers Taking Advantage of Their Employee Benefits? Benefit Resource ebook.

Put Money Back in Your Classroom Finding the hidden revenue in your pharmacy benefits

Evaluate the Current Biosimilar Landscape and Strategies to Secure Access. Jim Van Lieshout August 16, 2017

Medicare Drug Discount Cards: A Work in Progress

The Pharma/Payer Relationship Strategies for the Next Two Years

EU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers

Johnson & Johnson s trusted and experienced guide. to patient adherence and acquisition

New WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research

WORKSHOP B Monitor MSL and Field Force Compliance

YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.

Recommendations for Strengthening the Investigator Site Community

Health Reform for New Health Reform Reporters Kaiser Family Foundation July 7, 2016

San Francisco Health Service System

Control Costs and Increase Employee Engagement With Consumer Advantage

The U.S. Food and Drug Administration (FDA) is expected

ARNOLD & PORTER UPDATE

THE BIOLOGIC DRUG MARKET. ebook: The current state of biologic drugs and the challenges ahead

Workshop on Access to and Uptake of Biosimilar Medicinal Products

Healthcare Payers: In Pursuit of Four Digital Objectives

WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT

Key Regulatory Issues in Biosimilars

Executive Summary PBM Purchasers Guide A Quality Management Toolkit

The transition to OptumRx is designed to help us better serve your employees and help improve their overall experience:

Reward Your Health. Live well. Get rewarded.

2018 ACR Health Policy Statements

Derm Drugs: The Price is Too Darn High!

Utilize Real World Data to Optimize Patient Savings Programs. Mason Tenaglia Vice President, IMS Institute, Payer and Managed Care Insights

Planning for Successful Medical Device Reimbursement:

A High-Touch Approach to Improving Patient Access. Using field support to navigate reimbursement challenges

Overview and Life Cycle Planning for Biosimilars

A critical review of the current landscape Presentations

Publications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity

MORE OF WHAT MATTERS. Update: UnitedHealthcare Pharmacy Benefit Transition. February 26, 2013

W orksite wellness programs are becoming increasingly

Pharmaceutical Compliance Congress: Pricing Update

Global Forum on Competition

Coding Systems Understanding NDC and HCPCS

Section I: Pharmaceuticals and Medical Devices

2016 CSR Report Summary

ehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014

The Challenge of Pricing Combination Therapies

UFCW & Employers Benefit Trust

Proven Methods for Accelerating Cost Reduction. Richard Peters, Sr. Director of Surgical Services, Provista

STATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY

Pharmaceutical Sector Governance in the Middle East and North Africa Region A Regional Review by the World Bank

A spec i a l r e p o r t w ri t t e n i n a s s o c i at i o n w i t h I M S

New Cardinal Health (Post-Spin)

2018 Healthcare Industry Outlook Elevate Your Perspective

Walgreens Rx Supply Chain Transforming to an Outsource Model

Access Based Network Design A new approach to significantly reducing prescription drug benefit costs.

LEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017

Your Prescription Drug [ or 20%] Plan with Refill By Mail

OIG Increases Auditing of Pharmaceutical Manufacturers: Coupons, Part D Remuneration and Medicaid Rebate Administration

FOCUS REIMBURSEMENT STRATEGY TO DEMONSTRATE FULL VALUE STORY

Specialty Drug Spending

Insights from a Seven- Year, Multi-Stakeholder Initiative

Technology Solution Partners Featured:

Project Destiny Summary

INTERNATIONAL DIFFERENCES IN DRUG PRICES

@ALSETF #EAP2015. Jess B. Rabourn CBI Expanded Access Conference July 22, 2015

Transcription:

Innovative Approaches to Saving Patients Money on Prescription Drug Costs April 2018 1 Innovative Approaches to Saving Patients Money on Prescription Drug Costs

Executive Summary As prescription drug prices continue to rise and enrollment in high-deductible plans grows, many patients are shouldering higher costs for their prescription medicines. When these higher costs lead to patients not taking their medications as recommended, the health and financial consequences of non-adherence can negatively impact individuals and public and private payors alike. Recognizing this challenge, CVS Health has launched a comprehensive program to help patients save money on their prescription drugs. The enterprise initiative combines industry-leading capabilities to identify savings opportunities in realtime for patients at the pharmacy counter with best-in-class pharmacy benefits management solutions to increase cost transparency for patients, providers and pharmacists. Nearly 90% of PBM plan members spent less than $300 out-of-pocket for their prescription medicines in 2017. An Era of Rising Drug Prices In 2016, the U.S. spent $328.6 billion on prescription drugs, and by 2026 the country is projected to spend $462.5 billion according to National Health Expenditure data. Rising prescription drug spending is largely driven by significant increases in list prices by pharmaceutical manufacturers. As a retail pharmacy and a pharmacy benefit manager, CVS Health is in a unique position to address the challenges patients face in an environment of rising drug prices. CVS Caremark employs a number of pharmacy benefit management strategies to keep costs affordable for patients by maximizing the use of lowcost generics and biosimilars through formulary management and effectively negotiating discounts and rebates with drug manufacturers. As a result of these strategies, nearly 90 percent of PBM plan members spent less than $300 out-ofpocket for their prescription medicines in 2017. In 2017, 28% of workers were in a high deductible health plan. Today the vast majority nearly 90 percent of prescriptions filled each year in the U.S. are generic medicines, which are a key tool in driving down prescription drug costs. At CVS Pharmacy, more than 50 percent of the prescriptions filled cost $4 or less, and 75 percent cost $10 or less. Still, we recognize that for far too many Americans, prescription drug costs can be a major expense, which is why in April 2018 CVS Health announced an expanded comprehensive approach to help patients save money at the pharmacy counter. As the rise in high deductible health plans shifts more costs to patients, developing solutions that help individuals access and afford the medicines they need is an important public health and economic challenge. The Rise in High Deductible Health Plans The growing prevalence of high deductible health plans is playing a significant role in the costs patients are responsible for at the pharmacy counter. The percentage of workers in a high deductible plan has grown from four percent in 2006 to 28 percent in 2017. 2 Innovative Approaches to Saving Patients Money on Prescription Drug Costs

As patients assume more responsibility for their cost of care, rising prescription drug prices can lead to non-adherence and negative health outcomes. In fact, a survey of more than 2,400 CVS pharmacists revealed that 62 percent believe the high cost of drugs is the biggest reason why patients don t adhere to their medications. Medication non-adherence can lead to poor health outcomes and is estimated to cost the U.S. health care system nearly $300 billion each year. Comprehensive Solutions to Help Patients Access the Medicines They Need CVS Health is taking a leading role in developing programs to help patients save money on their overall prescription drug costs and stay on the medications they need. At a time when prescription drug prices are rising, our size, scale and ability to effectively negotiate with manufacturers help us mitigate the impact for both payors and patients. Industry-leading Innovation Focused on Saving Patients Money At the Pharmacy Counter With over 30,000 pharmacists in nearly 10,000 retail locations nationwide, our pharmacists have the expertise and access to patients to play a critical role in helping patients navigate the growing costs and increasing confusion surrounding prescriptions drugs. Medication non-adherence costs the health care system nearly $300 billion each year. 30,000 pharmacists serve 10,000 communities across the country. The CVS Pharmacy Rx Savings Finder will enable the retail pharmacists for the first time to evaluate quickly and seamlessly individual prescription savings opportunities right at the pharmacy counter. The Rx Savings Finder will help pharmacists navigate in a step-by-step fashion through each of the following options: 1. First, if the prescribed medication is on the patient s formulary and is the lowest cost option available. 2. Second, if there are lower-cost options covered under the patient s pharmacy benefit such as a generic medication or therapeutic alternative with equivalent efficacy of treatment. 3. Third, if the patient may be able to save money by filling a 90-day prescription rather than a 30-day prescription. 4. Finally, if neither a generic nor a lower-cost alternative is available, other potential savings options for eligible or uninsured patients where allowed by applicable laws and regulation. 1 With these tools and programs, our pharmacy teams are able to offer patients advice not only on how and when to take their medications, but also on how to better afford them. 1 Prescriptions submitted for reimbursement to Medicare, Medicaid or other federal or state programs are not eligible. 3 Innovative Approaches to Saving Patients Money on Prescription Drug Costs

At the Doctor s Office CVS Health recently launched a real-time benefits program, which helps bring greater drug price transparency to physicians and CVS Caremark plan members. Before a medication is prescribed, physicians have visibility to a member s specific benefit information, including the member-specific cost for a selected drug, based on a member s coverage, deductible and how much of the deductible they have met, along with up to five lowest-cost, clinically appropriate therapeutic alternatives based on the patient s formulary. PBM members have access to the same information on the CVS Caremark app and member portal. Early results show that the vast majority of prescribers accessing the real-time benefits information through their electronic health record switched their patient s drug when it is not covered, and they frequently switch from a drug that is covered under the member s plan to a less expensive available option. When the prescriber switched to a lower cost drug, the difference was approximately $75 per prescription. Using Pharmacy Benefit Management Solutions CVS Health s Point of Sale (POS) rebate offering allows the value of negotiated rebates on branded drugs to be passed on directly to patients when they fill their prescriptions. CVS Health has offered Point of Sale (POS) rebates to clients since 2013 and today nearly 10 million members are covered by and able to benefit from the program and the savings from this program can be significant. Clients may also adopt preventive drug lists, which make medications for many common, chronic conditions available at a $0 copay to the member. In 2017, members overall prescription cost share dropped by nearly one percent per member per month, as a result of increased adoption of preventive drug lists coupled with higher utilization of generic drugs. In 2017, CVS Health PBM strategies reduced drug trend for CVS Caremark commercial clients to the lowest level in five years, keeping drug price growth at a minimal 0.2 percent despite manufacturer price increases of near 10 percent. In fact, 42 percent of CVS Caremark payor clients spent less on their pharmacy benefit plan in 2017 than they had in 2016. CVS Caremark helped members reduce monthly out-of-pocket costs and improve adherence in key categories like diabetes, hypertension and hyperlipidemia. These lower costs, in turn, helped improve adherence in key categories such as diabetes, high blood pressure and high cholesterol. For example, plan designs that promoted lower-cost options and targeted adherence interventions helped increase the percentage of members who stayed on their therapy and were optimally adherent to their medications by as much as 1.8 percentage points. When prescriber using real-time benefits information switched to a lower cost drug, the difference was approximately $75 per prescription Leveraging Biosimilars for Savings As the first major PBM to place a biosimilar on formulary, CVS Health placed Zarxio on our national formulary in 2017 to replace higher cost Neupogen. Prior to this action, only 3 percent of patients covered by our commercial clients were receiving Zarxio through the pharmacy benefit. By July of the first year, 91 percent of patients were receiving the lower cost Zarxio instead. Later, we followed up by placing the biosimilar Basaglar on our formulary to replace more costly insulin treatments and continue to evaluate adding other biosimilars to our formularies. 4 Innovative Approaches to Saving Patients Money on Prescription Drug Costs

Effective Public Policy Would Allow More to Be Done to Lower Prescription Drug Costs Mitigating rising prescription drug prices works best when there is competition in the pharmaceutical market and when barriers to develop innovative solutions are addressed. If implemented, a number of public policies would help reduce the rise of drug prices: Reduce the backlog: FDA must continue to address the generic drug application backlog in order to create additional competition in the market place and lower the cost of prescription drugs. Expedited review: FDA must continue its efforts to provide expedited review for drugs with no current competition. Biosimilars: Increase the availability of biosimilars to make lower cost options available. Reduce biologic exclusivity: Shorten the exclusivity period for biologics from twelve to seven years. Interchangeability: FDA should finalize industry guidance for biosimilars in order to create a clear and consistent approval pathway for these important products. Curb anti-competitive behaviors: Stop practices that delay entry of competitive products, including pay-for-delay. Pass the CREATES Act: Stop the misuse of Risk Evaluation and Mitigation Strategies (REMS). Allow generic and biosimilar manufacturers to obtain samples of brand drugs to generate generic competition. Strengthen health savings accounts (HSAs): Modify HSA rules to give high deductible plans the option to cover all prescription drugs including generic and brand drugs outside the deductible. Address the Anti-Kickback Statute: Allow plans and manufacturers to enter into value-based purchasing programs incentivizing medication adherence. For more information on how CVS Health is helping patients access and afford prescription drugs, visit: cvshealth.com/savingpatientsmoney. 5 Innovative Approaches to Saving Patients Money on Prescription Drug Costs